ºÚÁÏÍø´óʼÇ

AZX Biotech uses a naturally occurring biological recombinant protein that stimulates cartilage growth. The advantage is that the original function of this protein is to target the body's natural pathway for cartilage growth. The team has shown that pain and inflammation are suppressed while cartilage is regenerated. It aims to establish its technology and commercialisation with the vision of serving the global population. AZX Biotech has a decades-long relationship with US-based regulatory consultants and is in early discussions with HTA experts.

• Osteoarthritis is the most common chronic joint disease with no treatment.
• Current options range from temporary symptomatic pain relief to total joint replacement surgery for severe arthritis. Surgery carries high risks.

• The entire spectrum of osteoarthritis patient profiles at the clinical level
• Frontline clinical practices
• Healthcare reimbursement schemes
• Orthopaedic surgery departments
• There is also an existing MBS code for knee injections and an established revenue cycle pathway, into which AZX Biotech’s product will fit seamlessly

• AUD500K seed funding (cash and in kind) to support early research efforts
• Positive initial preclinical data results
• Supply agreement with manufacturing partner that includes material and data related to CMC, tox study, and regulatory support
• Early engagement with venture partners to focus on inflection-point milestones for investment purposes